% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Sommerhuser:284775,
author = {G. Sommerhäuser and M. Karthaus and A. Kurreck and A.
Ballhausen and J. W. Meyer-Knees and S. Fruehauf and U.
Graeven and L. Mueller and A. O. Koenig and L. F. V.
Weikersthal and E. Goekkurt and S. Haas and A. Stahler and
V. Heinemann$^*$ and S. Held and A. H. S. Alig and S.
Kasper-Virchow$^*$ and S. Stintzing$^*$ and T. Trarbach and
D. P. Modest$^*$},
title = {{P}rognostic and predictive impact of metastatic organ
involvement on maintenance therapy in advanced metastatic
colorectal cancer: {S}ubgroup analysis of patients treated
within the {P}ana{M}a trial ({AIO} {KRK} 0212).},
journal = {International journal of cancer},
volume = {154},
number = {5},
issn = {0020-7136},
address = {Bognor Regis},
publisher = {Wiley-Liss},
reportid = {DKFZ-2023-02086},
pages = {863-872},
year = {2024},
note = {2024 Mar 1;154(5):863-872},
abstract = {Despite molecular selection, patients (pts) with RAS
wildtype mCRC represent a heterogeneous population including
diversity in metastatic spread. We investigated metastatic
patterns for their prognostic and predictive impact on
maintenance therapy with 5-fluorouracil/folinic acid ±
panitumumab. The study population was stratified according
to (1) number of involved metastatic sites (single vs
multiple organ metastasis), liver-limited disease vs (2)
liver metastasis plus one additional site, and (3) vs liver
metastasis plus ≥two additional sites. Kaplan-Meier method
and Cox regressions were used to correlate efficacy
endpoints. Single organ metastasis was observed in 133 pts
$(53.6\%)$ with 102 pts $(41.1\%)$ presenting with
liver-limited disease, while multiple organ metastases were
reported in 114 pts (46.0). Multiple compared to single
organ metastases were associated with less favorable PFS (HR
1.48, $95\%$ CI 1.13-1.93; P = .004) and OS (HR 1.37, $95\%$
CI 0.98-1.93; P = .068) of maintenance therapy. While
metastatic spread involving one additional extrahepatic site
was not associated with clearly impaired survival compared
to liver-limited disease, pts with liver metastasis plus
≥two additional sites demonstrated less favorable PFS (HR
1.92, $95\%$ CI 1.30-2.83; P < .001), and OS (HR 2.38,
$95\%$ CI 1.51-3.76; P < .001) of maintenance therapy.
Pmab-containing maintenance therapy appeared active in both
pts with multiple (HR 0.58; $95\%$ CI, 0.39-0.86; P = .006)
as well as to a lesser numerical extent in pts with single
organ metastasis (HR 0.83; $95\%$ CI, 0.57-1.21; P = .332;
Interaction P = .183). These data may support clinical
decisions when EGFR-based maintenance therapy is
considered.},
keywords = {maintenance therapy (Other) / metastases (Other) /
metastatic colorectal cancer (Other) / panitumumab (Other)},
cin = {BE01 / MU01 / ED01},
ddc = {610},
cid = {I:(DE-He78)BE01-20160331 / I:(DE-He78)MU01-20160331 /
I:(DE-He78)ED01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37840339},
doi = {10.1002/ijc.34760},
url = {https://inrepo02.dkfz.de/record/284775},
}